• Home
  • About Us
  • Services
  • Resources
  • Contact
  • CLOSE MENU

    About Us

    Precision analytics exists at the intersections of biology, medicine, applied math, and computer science through data. We are scientists with multi-disciplinary expertise in data science, computer science and software development, master protocol design, predictive and statistical modeling, machine learning, biomedicine, drug development, and regulatory policy.
    The Team

    The team behind Presagia

    Rick Landin

    PRESIDENT & CEO
    Dr. Landin has over 25 years of drug development experience ranging from preclinical to post-commercialization. His therapeutic areas of expertise include precision medicine, oncology, asthma and allergy, migraine, insomnia, depression, general anxiety disorder, multiple sclerosis, lupus, and rheumatoid arthritis. During his time in the industry, Dr. Landin has established a history of building, managing and leading Biometrics organizations in large R&D (Marion Merrell Dow, Eli Lilly, Biogen), small-to-midsize-pharma (IDEC, Neurocrine), as well as pre-commercialization (Ambit, Ignyta, La Jolla Pharmaceuticals). In addition, he has served and led cross functional, multi-corporate teams, leading to regulatory submission and approval of multiple products. Dr. Landin holds a Ph.D. is Statistics from Texas A&M University. Since graduating from Texas A&M, Dr. Landin has been committed to the practical application of statistical theory for the advancement of drug development, with successes including the following: development of the Theory of Selective Score Inflation to redesign depression studies, the creation of innovative endpoints for the measure of Sleep Maintenance, innovative data presentation of QTc data, and most recently serving as a catalyst in the development of a precision medicine toolbox based on advances in applied math/machine learning.

    Adam Sharp

    CHIEF FINANCIAL OFFICER
    Chief Financial Officer, 20+ years as a statistical programming consultant in the pharmaceutical industry. Chief Executive Officer of SimulStat Incorporated. Experience providing efficient, scalable operational and financial systems to support growth and profitability. BS in Statistics from Iowa State University.

    Mike Kane

    SCIENTIFIC ADVISOR
    Dr. Kane is an Assistant Professor of Biostatistics at Yale University. He was awarded John M. Chambers Statistical Software award for The Bigmemory Project. In 2012, named Co-PI for a grant in DARPA’s XDATA program, part of the Obama Administrations Big Data Initiative. Advisor for AT&T Labs Research on design and develop of petabyte-scale analysis infrastructure. Authored A Computational Approach to Statistical Learning. Expertise in the development of methods in statistical and machine learning with focuses on applications in clinical trials and population-scale human mobility.

    Brian Hobbs

    SCIENTIFIC ADVISOR
    Dr. Hobbs is Associate Professor at Dell Medical School, The University of Texas. He previously serve as Associate Staff and Section Head of Cancer Biostatistics at Cleveland Clinic and Co-Director of the Biostatistics and Bioinformatics Core for the Case Comprehensive Cancer Center. His methodological expertise comprises Bayesian inference, subtyping, prediction, and trial design as well as cancer radiomics. Before joining Cleveland Clinic, Dr. Hobbs was a tenured Associate Professor in the Department of Biostatistics at The University of Texas MD Anderson Cancer Center in Houston, Texas. In 2010, he completed a doctoral degree in biostatistics at the University of Minnesota and then joined MD Anderson as a postdoctoral fellow. Eastern North American Region of International Biometric Society selected his thesis paper for the John Van Ryzin Award in 2010. In 2016, Dr. Hobbs was selected by The University of Minnesota for the Emerging Leader Award, an honor bestowed on alumni on the basis of impactful contributions within 10 years of graduating from one of The School of Public Health’s 20 programs. In 2017, Dr. Hobbs was invited to lead the publication of National Cancer Institute’s Clinical Trials Design Task Force with the goal of providing national, consensus recommendations for first-in-human cancer drug trials that use seamless designs.

    David Hong

    SCIENTIFIC ADVISOR
    Dr. Hong is a Full Professor, Deputy Chair of the Department of Investigational Cancer Therapeutics, Associate Vice President of Clinical Research at MD Anderson Cancer Center. Extensive expertise in drug development for combination therapy and patient populations with other major comorbidities. Has published extensively on the clinical investigation of combination drug therapy, including multiple studies involving antibody therapeutics and/or immuno-oncology drugs. Recently his research endeavors have focused on developing personalized therapies for patients, whose tumors bear specific genetic mutations/amplifications and combining targeted therapies with immunotherapies.

    Jim Welsh

    Scientific Advisor
    Scientific Advisor, Head of Immuno Radiation, and Tenured Physician Scientist and faculty member at The University of Texas MD Anderson Cancer Center. Founder of OncoResponse and Molecular Match.